CEO Eric Finzi and COO Sebastian De Beurs to present on company's innovative neuromodulators for mental health at annual healthcare conference NEWPORT BEACH, Calif., Dec. 6, 2022 /PRNewswire/ --...

P-MUC1C-ALLO1 and P-BCMA-ALLO1 were well tolerated, with no dose-limiting toxicities (DLTs), cytokine release syndrome (CRS), graft vs host disease (GVHD) or immune effector cell-associated...

Nicholas Natasi, a student at Rowan University, won first place and $8,000 at the 39th annual Collegiate Entrepreneurs' Organization (CEO) Conference and Pitch Competition held on Oct. 28-30 in...

-- Fifteen abstracts underscore AbbVie's commitment to people living with migraine -- AbbVie to present late-breaking data from the Chronic Migraine Epidemiology and Outcomes – International...

Adagrasib in combination with pembrolizumab demonstrates favorable tolerability and promising preliminary efficacy in patients with first-line advanced/metastatic NSCLC harboring a KRASG12C...